Comparative study of ophthalmological and serological manifestations and the therapeutic response of patients with isolated scleritis and scleritis associated with systemic diseases

Abstract

Introduction: Scleritis is a rare, progressive and serious disease, the signs of which are inflammation and edema of episcleral and scleral tissues and is greatly associated with systemic rheumatoid diseases. Purpose: To perform a prospective and comparative study between ophthalmologic manifestations, serologic findings and therapeutic response of patients with isolated scleritis and scleritis associated with systemic rheumatoid disease. Methods: Thirty-two outpatients with non-infectious scleritis were studied, from March 2006 to March 2008. The treatment was corticoid eye drops associated with antiinflammatory agents, followed by systemic corticoids and immunosuppressive drugs if necessary, was considered successful after six months without scleritis recurrence. Results: Fourteen of 32 patients had scleritis associated with systemic rheumatoid disease, of which nine had rheumatoid arthritis, two systemic lupus erythematosus, one Crohn's disease, one Behçet's disease and one gout. There were no difference in relation to involvement and ocular complications, there was predominance of nodular anterior scleritis and scleral thinning was the most frequent complication. The scleritis associated with systemic rheumatoid disease group had 64.3% of autoantibodies, versus 27.8% among those with isolated scleritis and this difference was statistically significant. In the isolated scleritis group 16.7% used anti-inflammatory, 33.3% corticosteroids, 27.8% corticosteroids with one immunosuppressive drug, 5.5% two immunosuppressive drugs, 16.7% corticosteroids with two immunosuppressive drugs and 33.3% pulse of immunosuppressive drugs, there was remission in 88.9%. In the scleritis associated with systemic rheumatoid disease group 7.1% used anti-inflammatory, 7.1% corticosteroids, 50% corticosteroids with one immunosuppressive drug, 7.1% two immunosuppressive drugs and 22.2% pulse of immunosuppressive drugs, 100% had treatment success. Conclusion: Prevalence of unilateral nodular scleritis was noted in both groups and higher rates of all the parameters tested were noted in the scleritis associated with systemic rheumatoid disease group. There were no differences between the groups with respect to the use of immunosuppressive drugs and therapeutic response, which was fully satisfactory in the scleritis associated with systemic rheumatoid disease group and satisfactory in the isolated scleritis group.

Clinical Relevance of Autoantibodies and Inflammatory Parameters in Non-infectious Scleritis

“…In contrast to previous findings, scleritis associated with RA was characterized by severe complications. 14,15 The longer delay in time to 3 rd line treatment in our cohort might explain this finding.…”

Identifying TNF and IL6 as potential hub genes and targeted drugs associated with scleritis: A bio-informative report

“…4% to 10% of all reported cases are caused by infections with bacteria, such as Treponema pallidum, or viruses, such as varicella-zoster virus (3,4). It has also been associated with autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (5,6), as well as metabolic diseases like gout (7). Malignancy, surgical induction, or medication side effects have been suggested as possible causes of scleritis (8,9).…”

Review of the ophthalmic manifestations of gout and uric acid crystal deposition

“…Scleritis has been described in gout, manifesting as either anterior or posterior scleritis, and associated with tenonitis, characterized by severe pain, proptosis, chemosis and lid oedema . These cases of scleritis have been described in patients who had either coinciding features of gout, hyperuricemia or resolved scleritis after gout treatment with no other evidence to confirm the association between scleritis and gout.…”